We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ultrafast, Ultra-Sensitive Protein Detection Method Enables Ultra-Early Disease Diagnosis

By LabMedica International staff writers
Posted on 23 Dec 2022

Protein detection based on antigen–antibody reaction is vital in early diagnosis of a wide range of diseases. More...

Methods to analyze trace amounts of proteins based on antigen–antibody reaction enable diagnosis at an early stage of many diseases, including cancer, dementia, and microbial infections. However, such methods either have limited sensitivity or require complex and time-consuming processing to allow antigen–antibody reactions to occur. Now, a team of scientists has discovered a new principle underlying light-induced acceleration of antigen–antibody reaction, allowing for simple, ultrafast, and highly sensitive detection of proteins.

Aiming to accelerate antigen–antibody reactions, the researchers at Osaka Metropolitan University (OMU, Osaka, Japan) introduced target proteins and probe particles, with modified antibodies that selectively bind to the target proteins, into a channel that is as narrow as a human hair or artery and then applied irradiation with infrared laser light for three minutes, making it possible to carry out detection at a sensitivity approximately 100 times higher than that of conventional protein testing. The researchers achieved, for the first time, the rapid measurement of trace amounts of target proteins on the order of tens of attograms (ag = 10−18 g; one quintillionth of a gram) after only three minutes of laser irradiation.

The study results demonstrate that rapid and highly sensitive detection can be achieved by condensing proteins through the simple operation of confining them in a small space and irradiating them with a laser to accelerate the reaction. These findings will facilitate the detection of disease-related substances from a small amount of body fluids, such as a single drop of blood, and will assist in the discovery of novel disease markers, potentially leading to breakthroughs in the development of systems for ultra-early diagnosis of various diseases.

“The antigen–antibody reaction is a biochemical reaction that plays a crucial role in immunity, the body’s defense function,” explained lead researcher Professor Takuya Iida, Director of the Research Institute for Light-induced Acceleration System at Osaka Metropolitan University. “In an interdisciplinary collaboration beyond physics, chemistry, and biology, we uncovered a new principle underlying the control of antigen–antibody reaction by optical force, or light-induced force. I hope that the advantage of being able to measure trace markers with high sensitivity and speed by simple laser irradiation will aid in ultra-early diagnosis.”

Related Links:
Osaka Metropolitan University 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.